BioSpace News Archive

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the continued availability of NULIBRY (fosdenopterin) for Injection and the launch of Sentynl Cares.

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced the formation of a Scientific Advisory Board (“SAB”) for its INBRX-101 program for the treatment of alpha-1 antitrypsin deficiency (“AATD”).

Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2022.

CoNextions® Inc. (www.conextionsmed.com), an innovator in tendon repair, is pleased to announce that CoNextions TR® Tendon Repair System has received FDA 510(k) Clearance.

Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced that positive new data were presented at the 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings in Salt Lake City, Utah.

Cyteir Therapeutics, Inc., a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Adam Veness, Esq. has joined Cyteir as General Counsel.

Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that Prime Discoveries has successfully developed CovidDetect™, a rapid isothermal amplification diagnostic assay for detecting SARS-CoV-2.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the first participants have been enrolled in a study that is part of an 800-site master protocol trial for non-small cell lung cancer (NSCLC).

GlycoMimetics, Inc., announces that it will host a conference call and webcast to report first quarter financial results on Thursday, April 28, 2022, at 8:30 a.m. ET.

Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF (Pulsed Electro-Magnetic Field) product SofPulse®.